Arcus Biosciences (RCUS) Depreciation & Amortization (CF) (2017 - 2026)

Arcus Biosciences' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $9.0 million (down 10.0% YoY), while the FY2025 annual figure was $10.0 million, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.0 million, down from $3.0 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $3.0 million in Q4 2023, with the low at $1.0 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $2.0 million (2022), against an average of $2.1 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 200.0% in 2023, while the deepest fall reached 50.0% in 2023.
• Arcus Biosciences' Depreciation & Amortization (CF) stood at $1.0 million in 2022, then surged by 200.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025, then plunged by 33.33% to $2.0 million in 2026.
• Business Quant data shows RCUS's Depreciation & Amortization (CF) at $2.0 million in Q1 2026, $3.0 million in Q4 2025, and $2.0 million in Q3 2025.